这是一个低剂量CTX+IL2维持化疗有效小细胞肺癌的实验，实验结果显示维持治疗没有优势，只有那些接受预防性放疗的病人PFS、OS有延长趋势。但我认为这个实验的用药方式有问题，维持治疗在于低剂量而持久，这个实验设计的剂量不低，所以用药时间就不能持久，每次用药间隔差不多一个月呢，如何实现持续免疫提升和抗血管生成？
http://meetinglibrary.asco.org/content/94245-114
Background: huKS-IL2 immunocytokine is a humanized antibody specific for EpCAM, fused at its Fc end to two molecules of IL2. Results of a phase 1b study of huKS-IL2 plus low-dose CTX, and preclinical data, provided a rationale to evaluate this combination in SCLC, which is often EpCAM-positive.
Methods: Patients (pts) with ED-SCLC responding (PR/CR) to 4 cycles of first-line Pt-based chemotherapy were randomized 1,5:1 to receive huKS-IL2/CTX or best supportive care (BSC). Pts in the huKS-IL2/CTX arm received six 21-day cycles of CTX 300 mg/m2 on day (d) 1, and 1.5 mg/m2/d huKS-IL2 on d2–4, followed by 21-d cycles of CTX on d1 and huKS-IL2 on d2 until progression. Pts were stratified for prophylactic cranial irradiation (PCI) and response to chemotherapy. Primary endpoint was PFS rate at 6 months (mo). Secondary endpoints included OS rates at 12 and 18 mo from start of Pt-based chemotherapy, median PFS and OS, safety, and immunogenicity.
Results: 108 pts (64 huKS-IL2/CTX arm, 44 BSC arm) were randomized and treated. Baseline characteristics were balanced between arms; however, higher % of males (75 vs 61.4%) and of ECOG PS 0 (45.3 vs 38.6%) were observed in the active arm. Median age was 61.7 (32; 81) and 59.2 (45; 74) years in the active and BSC arm, respectively. Most pts were in PR at randomization (2 pts – 1 in each arm – had CR). PCI was used in 15 (23.4%) and 11 (25%) pts in the active and BSC arm, respectively. No significant differences in PFS or OS were observed in the active vs BSC arm: PFS rate was 6.4 vs 12.2%; median PFS was 1.5 vs 1.4 mo; OS rates at 12 and 18 mo were 52 vs 61% and 24 vs 29%, respectively; median OS was 12.3 vs 14.1 mo. One PR (45% reduction vs randomization baseline) was observed in the active arm. In a subset of pts who received PCI, median PFS was 1.7 vs 1.5 mo, median OS 21.5 vs 14.3 mo in the active vs BSC arm, respectively. AEs observed more frequently in the active arm were flu-like symptoms, rash, hypotension, lymphopenia, LFT and creatinine elevations; all Grade 3/4 AEs related to huKS-IL2 were reversible/manageable.
Conclusions: HuKS-IL2/CTX was well tolerated, but showed no benefit in pts with ED-SCLC in PR/CR after chemotherapy. A trend for improved PFS and OS was observed in pts who received prior PCI.
|
晚期肺癌经过4次换药，如今母亲已经4
作者：pears
“万事开头难”这句话在母亲的抗癌路上体现得淋漓尽致，最初确诊肺癌后半
既要，又要，还要，什么药品可以治疗
作者：seacat
EGFR突变可以分为常见突变和罕见突变。常见突变就是EGFR外显子19del突变
小细胞肺癌新希望？标准治疗耐药后OR
作者：Keenman
如果以药物规模化获批进入临床的时间来划分的话，进入21世纪以来，肺癌
母亲的基因检测和PD-L1报告出来了，
看了基因检测报告，似乎没有合适的靶向药，母亲确诊肺腺癌晚期，求助大家帮忙分析一下
异常凝血酶升高是复发吗？
23年12月底确诊。24年1和2月做了介入，3月份切除，5月和6月做了预防性介入。7月到11月
显身卡
